An example of this is the still unsettled role of CD4+ Tregs in early-stage, treatment-naive MM, with different studies reporting similar [21,22] increased [23,12], or decreased [24,25] frequencies when compared to healthy controls. This evidence concerns the gene CD4 and Miyoshi myopathy.